{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Glaxosmithkline Pharmaceuticals Ltd
Are Glaxosmi. Pharma latest results good or bad?
GlaxoSmithKline Pharmaceuticals reported a net profit of ₹257.49 crores for Q2 FY26, showing strong profitability growth but a 3.05% decline in revenue year-on-year, raising concerns about long-term revenue sustainability despite improved operational efficiencies.
How has been the historical performance of Glaxosmi. Pharma?
Glaxosmi. Pharma has shown consistent growth in net sales and profitability from March 2019 to March 2025, with net sales increasing from 3,128.12 crore to 3,749.21 crore and profit after tax rising from 445.39 crore to 927.58 crore. The company's operating profit margin improved significantly, reflecting enhanced operational efficiency.
Why is Glaxosmi. Pharma falling/rising?
As of 06-Nov, Glaxosmithkline Pharmaceuticals Ltd's stock price is 2,599.75, down 2.32%, and has been on a downward trend, losing 3.19% over the last two days. Despite strong management efficiency, the stock's high valuation and poor long-term growth prospects are negatively impacting investor sentiment.
GlaxoSmithKline Pharmaceuticals Q2 FY26: Premium Valuation Under Pressure as Growth Stalls
GlaxoSmithKline Pharmaceuticals Ltd. reported a modest net profit of ₹257.49 crores for Q2 FY26, marking a 25.60% quarter-on-quarter increase but a mere 1.98% year-on-year growth. The pharmaceutical major, with a market capitalisation of ₹44,633 crores, continues to grapple with anaemic top-line expansion whilst maintaining its premium valuation at 47 times trailing earnings. The stock has declined 2.32% following the results announcement, trading at ₹2,599.75 and reflecting investor concerns about the sustainability of its lofty multiples in the face of stagnating revenue growth.
Is Glaxosmi. Pharma technically bullish or bearish?
As of October 30, 2025, Glaxosmi Pharma's technical trend has shifted to a bearish stance, driven by bearish MACD, Bollinger Bands, moving averages, and KST indicators, despite a mildly bearish weekly outlook from Dow Theory.
Glaxosmithkline Pharmaceuticals Adjusts Evaluation Amid Mixed Financial Indicators and Market Trends
Glaxosmithkline Pharmaceuticals has recently experienced an evaluation adjustment, indicating a shift in its technical indicators. While the stock has performed well year-to-date, its annual return is modest compared to profit growth. The company faces challenges with a high Price to Book Value ratio and flat quarterly results.
Is Glaxosmi. Pharma technically bullish or bearish?
As of October 20, 2025, Glaxosmi. Pharma's trend is mildly bearish due to bearish weekly MACD and KST indicators, while daily moving averages also indicate short-term weakness, suggesting caution in the market.
How has been the historical performance of Glaxosmi. Pharma?
Glaxosmi. Pharma has shown steady growth in net sales and profitability from Mar'19 to Mar'25, with net sales increasing from 3,128.12 Cr to 3,749.21 Cr and profit after tax rising from 445.39 Cr to 927.58 Cr. The company also improved its operating profit margin and cash flow significantly during this period.
Is Glaxosmi. Pharma technically bullish or bearish?
As of October 15, 2025, the market trend has shifted to a moderately bearish stance, supported by bearish indicators such as the MACD, moving averages, and KST, while the mixed signals from Bollinger Bands and a mildly bearish OBV further reinforce this outlook.
GlaxoSmithKline Faces Technical Trend Shifts Amid Market Volatility and Mixed Indicators
GlaxoSmithKline Pharmaceuticals has recently experienced a revision in its evaluation, reflecting changes in technical indicators. The stock has shown significant volatility over the past year, with a year-to-date return of 22.19%, outperforming the Sensex. However, its five-year performance has lagged behind the index.
GlaxoSmithKline Stock Forms Death Cross, Signals Potential Bearish Trend
Glaxosmithkline Pharmaceuticals has recently encountered a Death Cross, signaling potential bearish momentum. With a market capitalization of Rs 46,502.00 Cr and a P/E ratio of 49.38, the stock has outperformed the Sensex year-to-date but faces short-term challenges, including recent declines and bearish technical indicators.
Glaxosmithkline Pharmaceuticals Adjusts Evaluation Amid Mixed Financial Performance Indicators
Glaxosmithkline Pharmaceuticals has recently experienced a change in its evaluation, indicating a shift in market sentiment. The company maintains strong management efficiency and a conservative debt profile, though long-term growth appears limited. Year-to-date performance has outpaced the broader market, despite recent declines in quarterly profits.
Is Glaxosmi. Pharma technically bullish or bearish?
As of 14 October 2025, the trend has shifted to mildly bullish, supported by daily moving averages and monthly Bollinger Bands, though caution is advised due to bearish weekly MACD and KST signals.
GlaxoSmithKline Pharmaceuticals Shows Mixed Technical Trends Amid Market Volatility
GlaxoSmithKline Pharmaceuticals has recently revised its evaluation amid fluctuating market conditions. The stock, currently priced at 2,760.00, has shown significant volatility over the past year. Its performance has notably outpaced the Sensex, with impressive returns year-to-date and over three years, reflecting the company's resilience in the market.
Is Glaxosmi. Pharma technically bullish or bearish?
As of September 25, 2025, the market trend is neutral with mixed signals: weekly indicators are mostly bearish while monthly indicators show some bullishness, indicating a lack of clear direction.
Glaxosmithkline Pharmaceuticals Faces Market Evaluation Shift Amid Stabilizing Performance Metrics
Glaxosmithkline Pharmaceuticals has recently adjusted its evaluation, indicating a shift in market position and technical indicators. The company reported flat financial performance for Q1 FY25-26, with modest annual growth in net sales and operating profit, while also experiencing a decline in profit before and after tax.
GlaxoSmithKline Pharmaceuticals Shows Mixed Technical Trends Amid Market Resilience
GlaxoSmithKline Pharmaceuticals has recently revised its evaluation amid current market dynamics. The stock has shown a modest annual return, outperforming the Sensex. Technical indicators present mixed signals, while the company has demonstrated significant resilience with strong year-to-date and three-year returns, highlighting its growth in the pharmaceutical sector.
How has been the historical performance of Glaxosmi. Pharma?
Glaxosmi. Pharma has shown consistent growth in net sales and profits from March 2019 to March 2025, with net sales increasing from 3,128.12 Cr to 3,749.21 Cr and profit after tax rising from 445.39 Cr to 927.58 Cr, alongside improved operational efficiency and cash flow. Total assets and liabilities also grew, reflecting balanced financial health.
Why is Glaxosmi. Pharma falling/rising?
As of 24-Sep, Glaxosmithkline Pharmaceuticals Ltd's stock price is 2,749.50, reflecting a recent decline of 0.38% and a total drop of 0.42% over the last two days. Despite strong management efficiency and year-to-date outperformance, recent trends indicate challenges in investor confidence and participation.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
